AU775079B2 - Pharmaceutical compositions and uses - Google Patents

Pharmaceutical compositions and uses Download PDF

Info

Publication number
AU775079B2
AU775079B2 AU52141/00A AU5214100A AU775079B2 AU 775079 B2 AU775079 B2 AU 775079B2 AU 52141/00 A AU52141/00 A AU 52141/00A AU 5214100 A AU5214100 A AU 5214100A AU 775079 B2 AU775079 B2 AU 775079B2
Authority
AU
Australia
Prior art keywords
acid
diphosphonic acid
hydroxy
diphosphonic
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU52141/00A
Other languages
English (en)
Other versions
AU5214100A (en
Inventor
Jonathan Green
Tetsuji Okuno
Jeanette Marjorie Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU775079(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9911926.5A external-priority patent/GB9911926D0/en
Priority claimed from GBGB9925131.6A external-priority patent/GB9925131D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU5214100A publication Critical patent/AU5214100A/en
Application granted granted Critical
Publication of AU775079B2 publication Critical patent/AU775079B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU52141/00A 1999-05-21 2000-05-19 Pharmaceutical compositions and uses Ceased AU775079B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9911926.5A GB9911926D0 (en) 1999-05-21 1999-05-21 Organic compounds
GB9911926 1999-05-21
GB9925131 1999-10-22
GBGB9925131.6A GB9925131D0 (en) 1999-10-22 1999-10-22 Organic compounds
PCT/EP2000/004562 WO2000071104A2 (en) 1999-05-21 2000-05-19 Use of bisphosphonic acids for treating angiogenesis

Publications (2)

Publication Number Publication Date
AU5214100A AU5214100A (en) 2000-12-12
AU775079B2 true AU775079B2 (en) 2004-07-15

Family

ID=26315578

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52141/00A Ceased AU775079B2 (en) 1999-05-21 2000-05-19 Pharmaceutical compositions and uses

Country Status (21)

Country Link
US (2) US20020142996A1 (enExample)
EP (1) EP1178810B8 (enExample)
JP (1) JP2003500352A (enExample)
KR (1) KR100763064B1 (enExample)
CN (1) CN1202828C (enExample)
AT (1) ATE293450T1 (enExample)
AU (1) AU775079B2 (enExample)
BR (1) BR0010808A (enExample)
CA (1) CA2374049A1 (enExample)
DE (1) DE60019580T2 (enExample)
DK (1) DK1178810T3 (enExample)
ES (1) ES2240106T3 (enExample)
HU (1) HUP0201329A3 (enExample)
IL (2) IL146520A0 (enExample)
NO (1) NO322212B1 (enExample)
NZ (1) NZ515541A (enExample)
PL (1) PL351674A1 (enExample)
PT (1) PT1178810E (enExample)
SK (1) SK16682001A3 (enExample)
TW (1) TWI224504B (enExample)
WO (1) WO2000071104A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287278B6 (sk) * 2000-06-20 2010-05-07 Novartis Ag Použitie kyseliny 1-hydroxy-2-(imidazol-1-yl)etán-1,1- difosfónovej na prípravu liečiva na liečenie stavov abnormálne zvýšeného kostného obratu
SI1591122T1 (sl) * 2000-06-20 2013-02-28 Novartis Ag Postopek za aplikacijo bisfosfonatov
CN1233325C (zh) * 2001-02-06 2005-12-28 罗亚尔·亚历山德拉儿童医院 治疗骨坏死和处理有发展为骨坏死危险的患者用的药物
RU2297229C2 (ru) * 2001-05-02 2007-04-20 Новартис Аг Фармацевтическое применение бисфосфонатов
ES2336312T3 (es) * 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
CA2763775C (en) 2002-05-10 2014-01-07 F. Hoffmann-La Roche Ag Bisphosphonic acids for the treatment and prevention of osteoporosis
DE60233576D1 (de) * 2002-12-02 2009-10-15 Innate Pharma Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
WO2005014006A1 (en) * 2003-07-21 2005-02-17 Novartis Ag Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
EP1723157B2 (en) † 2004-02-26 2017-02-08 Zentiva, k.s. Amorphous forms of risedronate monosodium
KR20070043043A (ko) * 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
US7914810B2 (en) 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2015018659A1 (en) * 2013-08-05 2015-02-12 Vib Vzw Glutamine synthetase inhibitors for inhibition of pathological angiogenesis
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608368A (en) * 1984-07-13 1986-08-26 Henkel Kommanditgesellschaft Auf Aktien 1-hydroxy-1,1-diphosphonic acids and cytostatic use thereof
WO1999038998A1 (en) * 1998-01-29 1999-08-05 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
SE9402001D0 (sv) * 1994-06-09 1994-06-09 Leiras Oy Pyridylbisphosphonates for use as a therapeutical agent
IT1290444B1 (it) * 1997-03-27 1998-12-03 Boehringer Mannheim Italia Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale
ES2269014T3 (es) * 1997-07-22 2007-05-01 MERCK & CO. INC. Procedimiento para inhibir la resorcion osea.
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
WO1999033473A1 (fr) * 1997-12-25 1999-07-08 Toray Industries, Inc. Remedes contre les maladies intramedullaires
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608368A (en) * 1984-07-13 1986-08-26 Henkel Kommanditgesellschaft Auf Aktien 1-hydroxy-1,1-diphosphonic acids and cytostatic use thereof
WO1999038998A1 (en) * 1998-01-29 1999-08-05 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIPMAN;LEUK LYMPHOMA, VOL.32, NO. 1/2, 1998, P 129-138 *

Also Published As

Publication number Publication date
US20040176327A1 (en) 2004-09-09
CA2374049A1 (en) 2000-11-30
DE60019580D1 (de) 2005-05-25
WO2000071104A2 (en) 2000-11-30
EP1178810B1 (en) 2005-04-20
IL146520A0 (en) 2002-07-25
CN1384749A (zh) 2002-12-11
AU5214100A (en) 2000-12-12
EP1178810A2 (en) 2002-02-13
NZ515541A (en) 2003-03-28
HUP0201329A2 (en) 2002-08-28
DE60019580T2 (de) 2006-03-09
IL146520A (en) 2006-09-05
KR100763064B1 (ko) 2007-10-04
NO20015638D0 (no) 2001-11-19
TWI224504B (en) 2004-12-01
ES2240106T3 (es) 2005-10-16
US20020142996A1 (en) 2002-10-03
BR0010808A (pt) 2002-08-27
DK1178810T3 (da) 2005-07-11
JP2003500352A (ja) 2003-01-07
WO2000071104A3 (en) 2001-07-19
HUP0201329A3 (en) 2005-02-28
EP1178810B8 (en) 2005-07-27
PT1178810E (pt) 2005-08-31
NO20015638L (no) 2002-01-15
ATE293450T1 (de) 2005-05-15
CN1202828C (zh) 2005-05-25
SK16682001A3 (sk) 2002-04-04
PL351674A1 (en) 2003-05-19
KR20010113830A (ko) 2001-12-28
NO322212B1 (no) 2006-08-28

Similar Documents

Publication Publication Date Title
AU775079B2 (en) Pharmaceutical compositions and uses
CA2427161C (en) Use of bisphosphonates for pain treatment
AU2001274109B2 (en) Method of administering bisphosphonates
AU2002257802B2 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
AU2002217061A1 (en) Use of bisphosphonates for pain treatment
US5965547A (en) Use of certain methanebishosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
AU2002257802A1 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
US20030212048A1 (en) Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
RU2261100C2 (ru) Применение бисфосфоновых кислот для лечения ангиогенеза
CA2183764C (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)